Journal of AdvancedMedical and Dental Sciences Research

Background: Colorectal carcinomas are one of the most frequent neoplasms in Western society. Lysosomal-β-galactosidase is a lysosomal enzyme that hydrolyzes the terminal β-galactose from ganglioside substrates and other glycoconjugates. Hence; we planned the present study to assess the activity of serum beta-galactosidase in colon cancer patients. Materials & methods: We planned the present study to assess of the activity of serum beta-galactosidase in colon cancer patients. A total of 10 colon patients and 10 healthy controls were included in the present study. We assessed the activity of β-galactosidase in the serum (pkat/ml) in duplicate by the colorimetric determination of p-nitrophenol released from p-nitrophenyl-β-D galactopyranoside by β-galactosidase. All the results were analyzed by SPSS software. Chi- square test was used for assessment of level of significance. Results: Mean activity of serum β-galactosidase in the patients of the study group and control group were 77.5 and 69.5 pkat/ml respectively. However; we didn’t observe any significant difference while comparing the mean serum β-galactosidase levels in between subjects of study group and the control group. Conclusion: β-galactosidase activity remains unaltered in colon cancer patients.
Key words: β-galactosidase, Colon cancer, Pathology.
Received: 22 November 2017 Revised: 28 November 2017 Accepted: 20 December 2017
Corresponding author: Dr. Himanshu Chauhan, Department of Pathology, BIMR Hospital Gwalior, Madhya Pradesh, India, E mail: him_himanshu11@ yahoo.co.in
This article may be cited as: Chauhan H. Assessment of Activity of Serum Beta-galactosidase in Colon Cancer Patients: A Pathological Study. J Adv Med Dent Scie Res 2018;6(1):135-137.